-
The Hong Kong Tiananmen vigil activists convicted in national security trial
-
Australia's Hussey mulls role with England for Ashes series
-
Eel-powered Japan whizz-kid, 11, chases Asian Games history
-
Indian captain 'scapegoat' in Britain's Russia shadow fleet case, wife says
-
Asian markets extend rally as traders assess US Treasuries pledge
-
Rosenior seeks to match Paris FC's capital ambition as Ligue 1 returns
-
Barcelona enter new era as Flick targets La Liga hat-trick
-
Inter set for Serie A title defence as Milan get Amorim reboot
-
Pogacar favourite for Vuelta with Grand Tour treble in sight
-
'Greatest' Springboks face All Blacks in clash of juggernauts
-
Bangladesh coach Simmons wary of Australia backlash in second Test
-
William and Harry: Britain's warring royal brothers
-
Hong Kong Tiananmen activists to receive national security verdict
-
UN holds second informal poll for next leader
-
Who are the candidates vying to lead the UN?
-
In US mining hub, black lung rates soar
-
Swiatek into Cincinnati semis after Rybakina injury
-
Champions Arsenal embrace being 'hunted' as Premier League returns
-
University suspends academic behind Jason Arday plagiarism charges
-
World No.2 Rybakina retires from Cincinnati clash with Swiatek
-
Key European leaders demand Israel halt West Bank settlement project
-
'I heard you missed me': Melania Trump jokes about month out of spotlight
-
Kiwi Ears Stardust: The Art of Natural Balance
-
IRA-Eligible Gold: Rules, Approved Coins, and Best Gold Dealers (Guide Released)
-
McIlroy bounces back to share BMW Championship lead
-
Amazon Prime Video to invest $2 bn in Latin America productions
-
Cobolli fueled by candy in sweet defeat of Paul
-
Panama Canal to reduce shipping over El Nino-fueled drought
-
Jailed Pakistan ex-PM Khan moved to hospital on court order: party
-
Maradona trial on hold over possible medical evidence mix-up
-
Pogacar eyes 'missing' piece ahead of Vuelta return
-
'Green dilemma': China's solar boom hurt birds, says study
-
US, Canada 'very close' to trade deal, Ottawa says, as details emerge
-
Pegula hangs on to dispatch Anisimova, reach Cincinnati semi-finals
-
Ronaldinho returns in search of 'beautiful' 300th goal
-
US charges woman with IS-inspired plot to blow up New York State Capitol
-
US pushes allies, China to back Trump's economic war on Iran
-
What a record-breaking El Nino could mean for the world
-
Former NBA MVP Harden reportedly set to return to Cavaliers
-
Duplantis edges Karalis to win Lausanne Diamond League pole vault
-
Brook makes Pakistan pay for drop as England dominate first Test
-
Alcaraz to return for US Open title defence
-
MemeCore Arrives on Nasdaq Through $1 Billion Landmark Treasury Transaction
-
China's rapid solar expansion hurt bird diversity: study
-
First US deportees land in Liberia
-
President Paul Biya back in Cameroon after 73 days away
-
US, Canada resume talks to finalize trade deal as details emerge
-
Newcastle boss Jaissle unfazed by lack of respect
-
Europe heatwaves scorch 80 million with 40 C heat: AFP analysis
-
US Open purse to top $100 mn as Grand Slams form player council
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
P.A.Mendoza--AT